Clinical trial prediction markets draw a Senate letter to HHS
Clinical trial prediction markets came under fire as two Democratic senators asked HHS what it is doing about bets on drug trials and FDA approvals.

Betting on medicine has reached Capitol Hill. Clinical trial prediction markets, which let traders wager on study results and Food and Drug Administration approvals, are the target of a letter sent on Wednesday, November 11, by Democratic Senators Angela Alsobrooks (Maryland) and Ron Wyden (Oregon) to Health and Human Services Secretary Robert F. Kennedy Jr., CNBC reported.
What happened
The senators asked what HHS has done to limit the risks. "Allowing individuals to bet on the success of these trials and drugs undermines the scientific process, creates perverse incentives for researchers, harms trial participants, and could lead to dangerous medical outcomes for untold numbers of Americans," they wrote.
They raised two specific worries: that the markets could sway patients deciding whether to join a study, and that researchers or regulators with nonpublic information could trade on it. The letter requests all internal HHS communications about staff use of prediction markets tied to matters the department governs, plus any contacts with the platforms or with the Commodity Futures Trading Commission, and any internal analysis of the markets' impact.
According to RG, Alsobrooks' office said traders have bet on FDA decisions for experimental drugs targeting obesity, Alzheimer's disease and several cancers.
The release added that many of the trials involved may be funded by the National Institutes of Health, which would put taxpayer-backed research at the center of the debate. In the letter the senators said HHS, the FDA and the NIH "must uphold the integrity of the drug development process" by putting guardrails in place. That framing treats clinical trial prediction markets as a public-health question, not only a financial-markets one, and points the request at the department rather than the CFTC alone.
Why it matters
Both leading platforms list these contracts, although Polymarket lists them only on its offshore venue, outside U.S. oversight. Kalshi introduced its versions in July with guardrails: only late-stage trials, listings only after enrollment closes and identity checks on all traders.
Kalshi pushed back. "The hypothetical concerns of the Senators apply equally to the equities market, which appears to be left out of their letter," spokesperson Jack Such told CNBC, arguing that the incentive for misconduct is far larger in stocks. Insider trading in prediction markets is already a live issue, as shown by the Pentagon's ban on staff using nonpublic information to bet.
The letter also shows how the political ground has shifted since the midterms, when the industry enjoyed a run of attention for its election forecasts. Clinical trial prediction markets now give newly empowered Democrats a fresh line of attack. CNBC has disclosed a commercial relationship with Kalshi.
What's next
HHS and Polymarket had not responded to CNBC at the time of its report. Watch for any HHS or FDA guidance on employee trading, and for whether the CFTC is drawn into the request.
CNBC's report on the letter is here.
This article is for information only and is not investment advice.